Adaptive Biotechnologies (ADPT) Non-Current Debt (2022 - 2026)

Adaptive Biotechnologies (ADPT) has 5 years of Non-Current Debt data on file, last reported at $124.7 million in Q1 2026.

• Quarterly Non-Current Debt fell 5.17% year-over-year to $124.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.7 million (down 5.17% YoY) and the FY2025 annual result came in at $126.6 million, down 4.42% from the prior year.
• Non-Current Debt declined to $124.7 million in Q1 2026 per ADPT's latest filing, from $126.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $132.7 million in Q3 2024, with the low at $124.7 million in Q1 2026.
• Average Non-Current Debt over 5 years is $129.5 million, with a median of $130.6 million recorded in 2023.
• Year-over-year, Non-Current Debt gained 4.71% in 2024 and declined 5.17% in 2026.
• Adaptive Biotechnologies' Non-Current Debt stood at $125.4 million in 2022, then rose by 4.23% to $130.7 million in 2023, then climbed by 1.34% to $132.4 million in 2024, then slipped by 4.42% to $126.6 million in 2025, then dropped by 1.44% to $124.7 million in 2026.
• Business Quant data shows ADPT's Non-Current Debt at $124.7 million in Q1 2026, $126.6 million in Q4 2025, and $129.4 million in Q3 2025.